Multi-centred Clinico-genetic Study of Actinic Prurigo in Thailand

NCT07055009 | Recruiting DMC

• 1 other identifier: CU41/2566
• Study Type: observational
• Target: 47
• Locations: 1 country
• Sites: 1

Brief Summary

This research project investigates the clinical and genetic associations of Actinic Prurigo (AP) in the Thai population. As a rare chronic photodermatosis, AP has been observed to occur more frequently in individuals with certain genetic predispositions, particularly specific Human Leukocyte Antigen (HLA) types. Previous studies have suggested variations in clinical presentation and HLA allele distributions between Asian and Western populations. The primary aim is to explore the relationship between clinical manifestations of AP and genetic profiles, including HLA typing, among Thai individuals. Additionally, the study seeks to examine whether different HLA types are associated with varying responses to treatment. The study design is a cross-sectional comparative study, involving both AP patients and age-matched healthy controls. Given the rarity of the condition, patient recruitment will be conducted across four collaborating institutions: King Chulalongkorn Memorial Hospital Siriraj Hospital Institute of Dermatology

Conditions

Actinic Prurigo

Keywords

Actinic prurigo; subtype actinic prurigo; HLA typing; genetic

Outcome Measures

Primary Outcomes (1)

• Targeted long-read HLA sequencing

  Correlation between the occurrence of Actinic Prurigo (AP), its clinical manifestations, and genetic factors-including HLA types-in individuals of Thai ancestry.

  through study completion, an average of 1 year

Secondary Outcomes (2)

• Short-read whole genome sequencing (WGS)

  through study completion, an average of 1 year

• Immunology study

  through study completion, an average of 1 year

Study Arms (2)

Case

Diagnostic Test: Targeted long-read HLA sequencing; Other: RNA extraction; Other: Full Skin examination

Control

Diagnostic Test: Targeted long-read HLA sequencing; Other: RNA extraction

Interventions

Targeted long-read HLA sequencing DIAGNOSTIC_TEST

Genetic study

Also known as: Short-read whole genome sequencing

Case; Control

RNA extraction OTHER

Nanostring technology, Seattle

Case; Control

Full Skin examination OTHER

Skin and mucosa examination

Case

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Actinic Prurigo (AP)

You may qualify if:

• Thai ethnicity
• Diagnosed with Actinic Prurigo (AP) according to the diagnostic criteria defined for this study
• Mentally competent, able to communicate, and able to read Thai.
• Participants receiving Thalidomide treatment must use two simultaneous methods of contraception, starting at least 4 weeks prior to initiating the medication and continuing throughout the treatment period and for at least 4 weeks after discontinuation.

You may not qualify if:

• History and physical examination findings suggestive of other photodermatoses such as Lupus erythematosus, Porphyria, or Polymorphous Light Eruption, among others.
• Elevated Epstein-Barr Virus (EBV) viral load detected in blood testing (EBV viral load will be tested in all participants).
• Low Minimal Erythema Dose (MED) to UVB radiation as the only abnormal finding.

Sponsors & Collaborators

• Chulalongkorn University: lead
• Health Systems Research Institute,Thailand: collaborator

Study Sites (1)

Faculty of Medicine Chulalongkorn University

Bangkok, Thailand

RECRUITING

MeSH Terms

Conditions

Actinic Prurigo

Central Study Contacts

Einapak Boontaveeyuwat, MD

CONTACT

+66922995700; einapak.b@chula.ac.th

Kittima Leklad

CONTACT

+6622564253; kittima.l@chula.ac.th

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2025
• First Posted: July 8, 2025
• Study Start: March 30, 2025
• Primary Completion (Estimated): May 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: July 8, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

TH (1)